Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
A

Ratings ESG MSCI

Ratings Bristol-Myers Squibb Company: Strengths and Weaknesses

  • The company presents an interesting fundamental situation from a short-term investment perspective.
  • The company has a good ESG score relative to its sector, according to MSCI.
Highlights: Bristol-Myers Squibb Company
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • The company is one of the best yield companies with high dividend expectations.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Analyst opinion has improved significantly over the past four months.
Weaknesses: Bristol-Myers Squibb Company
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company is in debt and has limited leeway for investment
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.

Rating Financials

Bristol-Myers Squibb Company SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Bristol-Myers Squibb Company SectorUnited States

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Bristol-Myers Squibb Company SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Bristol-Myers Squibb Company SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Bristol-Myers Squibb Company SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
123B
A
901B
A
585B
BBB
402B
AA
341B
AA
307B
AAA
300B
A
290B
A
203B
A
182B
AAA
Average 363.4B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. Ratings Bristol-Myers Squibb Company
SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW